Montreal, Canada
Optina Diagnostics, founded in 2011, is spearheading advancements in medical diagnostics through its innovative Retinal Deep Phenotyping platform. Their approach predominantly benefits the aging population, aiming to enhance precision medicine and tackle significant healthcare challenges.
Based in Canada, Optina leverages its FDA-cleared and Health Canada-licensed Optina-4C hyperspectral camera to introduce the power of spectral imaging to medical diagnostics. This technology, combined with AI-driven algorithms, offers groundbreaking insights into conditions like Age-related Macular Degeneration, Alzheimer's, and cardiac stenosis.
Notably, Optina has received the FDA's Breakthrough Device Designation for its Alzheimer's test, a substantial leap in differential dementia diagnosis. The company's progress was recently supported by a $2.10M Series A investment on January 24, 2022, with backing from the Alzheimer's Drug Discovery Foundation, reflecting strong investor confidence in their visionary solutions.
